Luminal A solid papillary breast carcinoma with lung metastasis: mastectomy and lung resection, PET-CT clear

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial breast tumor and lung metastasis were ER/PR positive, HER2 0

Metastatic Site: lung

About 40 days after lung surgery, PET-CT showed no abnormalities; the specialist recommended regular follow-up without additional antitumor drug therapy, and she was alive and in good condition.

PubMed CentralRead more →

Stage IV Breast Cancer: Dana's Patient Story

Patient Info: Dana, Female, 50s | Stage IV

Metastatic Site: Liver; bones; lymph nodes

As of October 2025, Dana was living with stable Stage IV metastatic breast cancer involving the liver, bones, and lymph nodes, controlled with targeted therapy and hormone blockers while also managing bipolar disorder and treatment-related mental health effects.

The Patient StoryRead more →

Stage IV Triple-Negative Breast Cancer: Melissa's Patient Story

Patient Info: Melissa Fouts, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: Outside the lungs / pleural area

As of September 2025, Melissa had been on low-dose eribulin for almost 7 years; 6 metastatic nodules outside the lungs had shrunk and stabilized, with 3 nearly undetectable on scans.

MD AndersonRead more →

Stage IV Breast Cancer: Maria's Patient Story

Patient Info: Maria, Female | Stage IV

Metastatic Site: Bone (spine, clavicle, rib, thigh bone, scapula);…

Maria initially had a clean PET scan after chemotherapy, surgery, radiation, and targeted/endocrine therapy, but later developed Stage IV metastatic breast cancer involving multiple bone sites, with lung and cervical-region involvement also described. As of September 2025, she remained on treatment and did not have an available clinical trial option.

The Patient StoryRead more →

Stage IV Breast Cancer: Iris's Patient Story

Patient Info: Iris, Female | Stage IV

Metastatic Site: Spine; liver; bone

As of August 2025, Iris was living with Stage IV metastatic breast cancer involving the spine, liver, and bones and was receiving systemic maintenance therapy with monthly injections and close monitoring.

Metastatic breast cancer to the mandible with later lung and liver spread

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER/PR negative, HER2 weak-to-moderate.

Metastatic Site: mandible/bone, lungs, liver

She died 6 months after diagnosis of mandibular metastasis from breast cancer, after further spread to the lungs and liver.

PubMed CentralRead more →

Stage IV Breast Cancer: Linda's Patient Story

Patient Info: Linda Norman, Female, 60s | Stage IV

Metastatic Site: Bone: humerus/shoulder region

As of August 2025, Linda was 1 year into treatment for bone-metastatic breast cancer with letrozole, Verzenio, and bone-strengthening infusions; scans showed the tumor had not grown and bone scarring suggested healing.

Metastatic hormone receptor-positive breast cancer: palbociclib and fulvestrant during dialysis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-negative; HER2 0 / HER2-negative; Ki-67 20.1%

Metastatic Site: lung, pleura, bone, right supraclavicular lymph node

As of August 2025, metastatic breast cancer had remained stable for 18 months on fulvestrant plus dialysis-adjusted palbociclib dosing, with hematologic toxicity managed through treatment interruptions, transfusion, and dose reduction.

PubMed CentralRead more →

Metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-positive breast cancer. Jaw workup focused on osteonecrosis

Metastatic Site: bone / osseous metastasis

The case focused on metastatic HER2-positive breast cancer complicated by medication-related osteonecrosis of the jaw after antiresorptive therapy; dental pain improved transiently after oral-surgery interventions, but systemic cancer response was not described.

PubMed CentralRead more →

Stage IV Breast Cancer: Suzy's Survivor Story

Patient Info: Suzy, Female | Stage IV

Metastatic Site: Bone

As of July 2025, Suzy was living with de novo Stage IV bone-metastatic breast cancer and had achieved no evidence of active disease after starting targeted treatment in May 2023.

Metastatic invasive lobular breast cancer with emergency surgery for bowel obstruction

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: peritoneum, ovaries, pelvic wall/pelvic mass, liver…

The patient had known metastatic invasive lobular breast cancer and recovered from emergency laparotomy for bowel obstruction, with discharge in stable condition on postoperative day 5.

PubMed CentralRead more →

HER2-positive breast cancer with brain, skin, and lymph-node metastases responding to dual-targeted therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: HER2-positive breast cancer. Initial tumor was ER/PR negative with Ki-67 30%; skin metastasis had Ki-67 70%.

Metastatic Site: brain, left cervical lymph nodes, skin of left chest…

After 1 cycle of inetetamab trastuzumab, pyrotinib, and capecitabine, skin metastases regressed, CEA and CA125 decreased, brain lesions shrank, and the largest lesion decreased by about 46%, meeting partial response; disease remained stable as of September 2024.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Elissa's Patient Story

Patient Info: Elissa, Female, Under 40 | Stage IV

Biomarkers: HER2-positive; no hereditary mutation reported

Metastatic Site: lymph nodes, liver, spine

Elissa had Stage IV HER2-positive metastatic breast cancer with an early strong response to systemic therapy, but she described the disease as long-term and not curative. As of July 2025, she had lived with metastatic breast cancer for about 4 years and had received roughly 5 lines of treatment.

The Patient StoryRead more →

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement responding to T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

HER2-low lobular breast cancer with bone marrow involvement treated with T-DXd

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial surgical specimen: ER-positive; PR-negative; HER2-negative. Bone marrow relapse: breast cancer infiltration with low HER2 staining.

Metastatic Site: bone marrow

Two years after starting T-DXd, this patient remained free of bone marrow disease and continued the same treatment regimen.

PubMed CentralRead more →

Stage 4 triple-negative breast cancer: NED after adrenalectomy

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; CA 15-3 elevated at recurrence; normalized post-surgery

Metastatic Site: adrenal gland

After adrenalectomy, serum CA15-3 and metanephrine/normetanephrine levels normalized, and the preoperative workup had found no other metastatic disease.

PubMed CentralRead more →

HER2-positive breast cancer with metastatic recurrence and complete response to T-DM1

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2 IHC 3+ and hormone receptor-negative in primary and metastatic breast cancer; no liver metastases seen.

Metastatic Site: major pectoralis muscle, lung, broncho-hilar lymph…

After complete radiologic response on T-DM1, treatment was stopped after 22 months because of porto-sinusoidal vascular disorder. Seven months later, she remained asymptomatic and under surveillance with no signs of recurrent disease.

PubMed CentralRead more →

Stage IV Breast Cancer: Queen's Patient Story

Patient Info: Queen, Female, Under 40 | Stage IV

As of June 2025, Queen was living with Stage IV/metastatic breast cancer after multiple surgeries, setbacks, spread, and another tumor, while focusing on faith, self-advocacy, and living each day fully.

The Patient StoryRead more →

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-FarberRead more →

Severe Melioidosis During Chemotherapy for Metastatic Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

A 58-year-old woman with metastatic breast cancer developed life-threatening melioidosis and severe low blood counts after her sixth chemotherapy cycle, requiring intensive infection treatment.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Jennifer's Survivor Story

Patient Info: Jennifer Masters, Female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Chest wall/skin near surgery incision; lymph nodes

As of May 2025, Jennifer had no reported recurrence for several years after Stage IV HER2-positive metastatic breast cancer responded completely to clinical-trial treatment with T-DM1 and neratinib; she continued annual Cleveland Clinic visits and remained active with family and volunteering.

Cleveland ClinicRead more →

Metastatic male breast cancer: complete metabolic response after restarting anastrozole, leuprolide, abemaciclib, zoledronic acid, and radiation

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER >95%; PR >95%; HER2/neu-negative; Ki-67 30%; PIK3CA exon 21 pathogenic variant; BRCA1 not mutated; BRCA2 not mutated

Metastatic Site: bone (vertebral bodies T2-T6, L1, and L5)

As of May 2025, after restarting endocrine and targeted therapy and receiving palliative radiation, the last two PET scans showed complete metabolic response without disease progression, and brain MRI showed no metastasis.

PubMed CentralRead more →

Metastatic ER-positive pleomorphic lobular breast cancer: psoas metastasis and stable disease on eribulin

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary and chest-wall recurrence were ER/PR positive, HER2 negative. Later psoas metastasis was ER positive, PR/HER2 negative.

Metastatic Site: skin of left chest wall; bone; left psoas muscle;…

As of May 2025, one year after diagnosis of malignant psoas syndrome from breast cancer metastasis, she remained on outpatient treatment with eribulin and had stable disease.

PubMed CentralRead more →